National Advisory Committee on Immunization (NACI): Membership and representation
The National Advisory Committee on Immunization (NACI) is a national advisory committee of experts in the fields of pediatrics, infectious diseases, immunology, pharmacy, nursing, epidemiology, pharmacoeconomics, social science and public health. NACI has been providing guidance on the use of vaccines currently or newly approved for use in Canada to the Government of Canada since 1964. The Committee reports to the Vice-President of the Infectious Disease Prevention and Control Branch, and works with staff of the Centre for Immunization and Respiratory Infectious Diseases of the Public Health Agency of Canada to provide ongoing and timely medical, scientific and public health advice.
NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are included in published literature reviews, statements and updates. NACI recommendations are also published in theCanadian Immunization Guide. Email updates are available through our mailing list.
Membership
Chair
Dr. Robyn Harrison
Alberta Health Services
Grey Nuns and University of Alberta Hospitals
Dr. Robyn Harrison is an Infectious Disease Specialist who works in Edmonton, Alberta. She is a Communicable Disease Consultant for the province wide Alberta Health Services Workplace Health and Safety Program (a position she has held since 2009). She has also served as consultant for the Covenant Health Alberta Occupational Health and Safety Program (2008-2014). Dr. Harrison is keenly interested in policy development and support for clinicians to prevent infection transmission in healthcare settings. She is a member of the Alberta Advisory Committee on Immunization, and she participates in infection prevention working groups in the province of Alberta, including past work on pandemic influenza H1N1 in 2009, and avian influenza is 2014. At a national level, she is working with the Public Health Agency of Canada as a member of the Prevention and Control of Occupational Infections in Health Care Settings Guideline Working Group to update and disseminate national evidence-based infection prevention and control (IPC) guidance.
Dr. Harrison obtained her medical degree at Dalhousie University, Nova Scotia; and she completed her Internal Medicine and Infectious Diseases subspecialty training at the University of Alberta. Most recently she completed an MSc in the combined areas of Public Health and Epidemiology through the London School of Hygiene and Tropical Medicine, England.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Co-investigator in the Canadian COVID-19 Cohort Study for healthcare workers: "Are healthcare workers at higher risk of COVID-19 than other working adults?" | CIHR | N/A | N/A | >1 time | Date interest arose: December 2020 Date interest ended: Ongoing |
Knowledge User | Pediatric outcome improvement through coordination of research networks (POPCORN) | N/A | N/A | >1 time | Date interest arose: 2021 Date interest ended: Ongoing |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid or voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Communicable Disease Consultant | Alberta Health Services | >1 time | Date interest arose: 2009 Date interest ended: Ongoing |
Alberta Advisory Committee on Immunization | Alberta Health | >1 time | Date interest arose: 2015 Date interest ended: Ongoing |
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Alberta Association of Travel Health Professionals (AATHP) conference (Presentation at a scientific meeting) Edmonton, AB |
AATHP | N/A | <$1,000 | One-time event | Date interest arose: September 2023 |
6. Sponsored travel
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
NACI PHAC supported travel to Ottawa | PHAC | N/A | <$1,000 | >1 time | Date interest arose: 2017 Date interest ended: Ongoing |
Pan-American Health Organization (PAHO) funded travel to the Meeting of the Regional NITAG Network | PAHO | N/A | $1,000-5,000 | One-time event | Date interest arose: Dec 3, 2023 Date interest ended: Dec 7, 2023 |
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Vice-chair
Dr. Vinita Dubey
Toronto Public Health
Dr. Vinita Dubey graduated from the University of Toronto's Public Health and Preventive Medicine Residency Program. She holds an Adjunct Professor appointment with the University of Toronto's Dalla Lana School of Public Health. Since 2006, she has been an Associate Medical Officer of Health for Toronto Public Health in Communicable Disease Control. Specializing with the Vaccine Preventable Disease program includes involvement in the school based vaccine program, immunization school assessment program which suspends students who are not up-to-date with required vaccines, adverse event following immunization investigations, and outbreak management including the 2017 mumps outbreak in Toronto which was the largest mumps outbreak the city has had in over 20 years. She also works as an emergency medicine physician in a small community hospital.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Members
Dr. Melissa Andrew
Dalhousie University
Halifax, Nova Scotia
Melissa K. Andrew is Professor of Geriatric Medicine at Dalhousie University in Nova Scotia, Canada. She did a Masters of Public Health at the London School of Hygiene and Tropical Medicine and completed her Interdisciplinary PhD at Dalhousie University on frailty and social vulnerability in older adults. She is an Associate Member of the Canadian Centre for Vaccinology and co-Principal Investigator of the Canadian Immunization Research Network Serious Outcomes Surveillance (SOS) Network, studying how frailty impacts influenza and COVID-19 vaccine effectiveness and clinical outcomes, especially in older people. She has worked on including frailty in vaccine clinical trials and serves on the Scientific and Executive Committees of the Global Influenza Hospital Surveillance Network.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples:
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Investigator on surveys of middle aged and older adults' knowledge, attitudes and beliefs, and experiences with influenza like illness impacting their function and activities. Two rounds of research surveys completed (one per year). | Sanofi | Institution | $50,000-100,000 | >1 time | Date interest arose:
2019 Date interest ended: Final paper being submitted Oct 2022 |
Principal Investigator of research studies on frailty in relation to zoster vaccine efficacy – a secondary analysis of data from two large RCTs. Two published papers to date, one in submission. | GSK | Institution | $100,000- 500,000 | One-time event | Date interest arose:
2018 Date interest ended: August 2022 |
PI on a grant the burden of RSV among hospitalized Canadian adults; conducted through the SOS Network | GSK | Institution | ≥$1,000,000 | One-time event | Date interest arose: Jan 2019 Date interest ended: Ongoing |
Investigator on a grant: Hospitalized Pneumococcal Pneumonia in Canadian Adults | Merck | Institution | >$1,000,000 | One-time event | Date interest arose: March 2023 Date interest ended: Ongoing |
Public Health Agency of Canada funding for influenza and COVID- 19 surveillance; run though Public Works Canada | PHAC contract |
Institution | >$1,000,000 | >1 time | Date interest arose:
2018 Date interest ended: March 2024 |
Global Influenza Hospital Surveillance Network – co- Principal Investigator of Canadian site | Fondation de France | Institution | $100,000- 500,000 | >1 time | Date interest arose:
2017 Date interest ended: Ongoing |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Ad hoc participation in advisory boards on COVID vaccine (and hesitancy), Pneumococcal vaccines: Nov 2019, Nov 2020, one meeting spread over virtual sessions in Oct, Nov 2021 and Feb 2022. No ongoing commitment between meetings. |
Pfizer | >1 time | Date interest arose: Nov 2019 Date interest ended: Nov 2021, Feb 2022 |
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the travel | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Travel expenses reimbursed to attend meetings of the Global Influenza Hospital Surveillance Network, or which I am a site investigator and member of the Scientific Advisory and Executive Committees | GIHSN/ Fondation de France |
Directly to the researcher | $1,000-5,000 | >1 time | Date interest arose:
2017 Date interest ended: Ongoing |
6. Sponsored travel
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Feb 8, 2025 at the Pediatric ID conference, Banff | N/A | Directly to the researcher | $509 | One-time event | Date interest arose: February 2025 |
May 21, 2025 Iqaluit to give a talk on newborn screening for severe combined immunodeficiency where I also discussed the use of IVIG and SCIG | CSL Behring | N/A | <$3,000 | One-time event | Date interest arose: May 2025 |
7. Hospitality
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
Describe the hospitality | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Feb 8th 2025 at the Pediatric ID conference, Banff | N/A | Directly to the researcher | N/A | One-time event | Date interest arose: February 2025 |
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topic
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published | Funds allocated to | Total dollar amount | Recurrence | When the statement happened |
---|---|---|---|---|
Written many papers which advocate for improved vaccination development and uptake in older adults. No specific products advocated for except for products that are already approved/recomme nded by NACI. No payments. | N/A | N/A | >1 time | Date interest arose: Date interest ended: Ongoing |
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to Vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Nicholas Brousseau
Québec, QC
Dr. Nicholas Brousseau is a specialist in preventive medicine and completed his education at Laval University in 2011. Following his education, he completed a research fellowship on vaccine-preventable diseases at Public Health England in London. Dr. Brousseau joined the Institut national de santé publique du Québec in 2015 and the Centre de recherche du CHU de Québec - Université Laval in 2019. He has been a Member of the Quebec Immunization Committee since 2016. He is also a Clinical Associate Professor at Laval University.Dr. Brousseau conducts research on vaccine-preventable diseases. His areas of expertise are vaccination against pertussis, tetanus, pneumococcus, influenza and COVID-19 (immunogenicity, efficacy and impact of vaccination). He also conducts work on the optimization of vaccination services in Quebec. In 2020, he established a study on the seroprevalence of antibodies against the COVID-19 virus in health care workers in 10 hospital centers in Quebec.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Principal Investigator Evaluation of the impact of changes to pertussis vaccination in Quebec |
Quebec Ministry of Health and Social Services Institution | Institution | $100,000-500,000 | N/A | Date interest arose: 2020 Date interest ended: 2023 |
Sub-investigator Pertussis Vaccination in Pregnant Women: Implementation and Evaluation of Different Vaccination Delivery Models |
Quebec Ministry of Health and Social Services Institution | Institution | $100,000-500,000 | N/A | Date interest arose: 2020 Date interest ended: 2023 |
Sub-investigator Effectiveness of COVID-19 vaccines |
Quebec Ministry of Health and Social Services Institution | Institution | $100,000-500,000 | N/A | Date interest arose: 2021 Date interest ended: 2023 |
Sub-investigator Acceptability of RSV vaccination. |
Quebec Ministry of Health and Social Services | Institution | $10,000- 100,000 | N/A | Date interest arose:2023 Date interest ended: - |
Principal Investigator Single-dose effectiveness of mpox vaccine in Quebec, Canada |
Quebec Ministry of Health and Social Services | Institution | $100,000- 500,000 | N/A | Date interest arose:2022 Date interest ended: - |
Principal Investigator Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children |
Quebec Ministry of Health and Social Services | Institution | $100,000- 500,000 | N/A | Date interest arose:2023 Date interest ended: - |
Principal Investigator Does a reduced-dose RotaTeq (RV5) vaccine schedule translate into a higher incidence of rotavirus infections compared to approved RV5 schedules? |
CIRN | Institution | $100,000- 500,000 | N/A | Date interest arose:2023 Date interest ended: - |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Member of the Comité sur l'immunisation du Québec (CIQ) | None (committee under the auspices of the INSPQ) | N/A | Date interest arose: 2016 Date interest ended: Ongoing |
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Presentations at scientific conferences, including the Canadian Immunization Conference (CIC) | N/A | N/A | N/A | >1 time | Date interest arose: Ongoing Date interest ended: Ongoing |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topic
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published | Funds allocated to | Total dollar amount | Recurrence | When the statement happened |
---|---|---|---|---|
Media interviews to discuss Quebec Immunization Committee recommendations | N/A | N/A No income obtained | N/A | Date interest arose: Date interest ended: |
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Arianne Buchan
The Ottawa Hospital
Ottawa, Ontario
Dr. C. Arianne Buchan completed her medical degree at Queen's University in 2010 and both her Internal Medicine and Infectious Diseases training at the University of Ottawa. She pursued a Transplant and Immunocompromised Host Fellowship at Massachusetts General Hospital followed by a Science Masters in Epidemiology at the Harvard T.H Chan School of Public Health. She currently practices Infectious Diseases at The Ottawa Hospital where she was recently appointed the Medical Director of Transplant Infectious Diseases. She is an Assistant Professor and the Program Director for Adult Infectious Diseases Training Program at the University of Ottawa. As a clinician investigator with the Ottawa Hospital Research Institute (OHRI), her main area of research interest is in the prevention and prediction of infection in immunocompromised hosts, including research surrounding immunizations in this vulnerable population.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
A prospective multi-site observational study of SARS-COV-2 vaccination immunogenicity in patients with hematologic malignancies: The VIP Study Nominated PI |
CITF / PHAC | Institution | >$1,000,000 | One-time event | Date interest arose: 2021 Date interest ended: ongoing, funding runs out in 2023, we expect publications and presentations in 2023-2024 |
A prospective multi-site observational study of SARS-COV-2 vaccination immunogenicity in patients with hematologic malignancies: The VIP Study Hybrid Immunity Grant Nominated PI |
CITF/PHAC | Institution | $500,000-1,000,000 | One-time event | Date interest arose: 2021 Date interest ended: ongoing, funding runs out in 2023, we expect publications and presentations in 2023-2024 |
Optimizing COVID-19 immunization in patients with adverse events following immunization in the Special Immunization Clinic Network Co-Investigator, site PI |
CITF / PHAC | Institution | $500,000-1,000,000 | One-time event | Date interest arose: 2021 Date interest ended: ongoing, funding runs out in 2023, we expect publications and presentations in 2023-2024 |
Canadian Immunization Research Network: COVID-19 Vaccine Readiness Co-Investigator, site PI |
CIHR | Institution | >$1,000,000 | One-time event | Date interest arose: 2020 Date interest ended: ongoing, funding runs out in 2023, we expect publications and presentations in 2023-2024 |
Barriers, Enablers & Adherence to Immunization Practices in Adult Patients Post-Hematopoietic Stem Cell Transplant PI |
TOHAMO Innovation Fund, The Ottawa Hospital | Institution | $50,000-100,000 | One-time event | Date interest arose: 2020 Date interest ended: 2024 |
Infectious complications in patients with Multiple Myeloma - A Prospective Observational Study PI |
Department of Medicine, University of Ottawa | Researcher | $10,000-50,000 | One time event | Date interest arose: 2024 Date interest ended: 2026 |
Canadian Immunization Research Network (CIRN) Co-Investigator |
CIHR | Researcher | >$1,000,000 | One time event | Date interest arose: 2024 Date interest ended: 2029 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Hélène Decaluwe
Research Centre of the Sainte-Justine University Hospital
Montreal, Quebec
Hélène Decaluwe is Associate Professor in the Immunology and Rheumatology Division of the CHU Sainte-Justine (Department of Pediatrics, University of Montreal) since 2010 and Clinician Scientist and outgoing Deputy Head of the Immune Diseases and Cancer Research Axis at the CHU Sainte-Justine Research Center. Dr. Decaluwe graduated from the Faculty of Medicine at McGill University and completed her residency in pediatrics at the CHU Sainte-Justine (University of Montreal). She then completed her training in pediatric clinical immunology at the Necker Enfants-Malades Hospital (Paris, France) with Professor Alain Fischer. Her research training includes a Master and a PhD degree in immunology at Pierre and Marie Curie University (Paris 6) carried out in the laboratories of Professor Jean-Laurent Casanova and Professor James Di Santo respectively. Clinical researcher supported by the Fonds de Recherche du Québec en Santé (FRQS), she has dedicated her career to resolving the mechanisms of T cell differentiation in health, infection and primary immune deficiencies. The primary focus of her research is to better understand the role of cytokines in the differentiation of T cells in health and disease, and to develop novel immunotherapeutic approaches that target cytokine-dependent pathways and inhibitory receptors expressed on T cells, to cure chronic viral infections and cancer. Supported by both national (Canadian Institutes of Health Research, National Institute of Health) and private (Canadian Cancer Society/Cole Foundation, Charles Bruneau Foundation, Leukemia and Lymphoma Society of Canada) funding agencies, her laboratory has established a solid expertise in the field of T cell exhaustion, a differentiation pathway that limits optimal T effector cell functions and precludes memory T cell development. She is particularly involved in identifying the cytokine-dependent signaling pathways and transcription factorsregulating T cell exhaustion during disease. She further aims to develop novelcombined immunotherapeutic approaches that target inhibitory receptors and/or cytokine-dependent signaling pathways, to improve cure rates in cancer refractory patients and patients with primary immunodeficiencies. Hélène Decaluwe in also in recognized expert in the immune reconstitution of severe combined immunodeficiency patients treated by stem cell transplantation and aims to inform on the best therapeutic approaches to transplant these patients. Since the beginning of the current COVID-19 pandemic, her laboratory has been investigating T-cell immune correlates of protection to SARS-Cov-2, induced by natural infection and vaccination, through research initiatives supported by the Canadian Institutes of Health Research and the COVID-19 Immunity Task Force.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
REinfection in COVid- 19 Estimation of Risk (RECOVER) - Phase 2 Vaccine; NPI C Quach; co-investigator |
Public Health Agency of Canada (PHAC) -through the CITF | Institution | $500,000-1,000,000 | One-time event | Date interest arose: Apr 2021 Date interest ended: Mar 2023 |
Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study); NPI A Pham-Huy; co-PI |
Children's Hospital Academic Medical Organization (CHAMO) Innovation fund |
Institution | $50,000-100,000 | One-time event | Date interest arose: Apr 2021 Date interest ended: Mar 2022 |
Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study); NPI A Pham-Huy; co-PI |
Physicians Services Incorporated Foundation (The PSI) | Institution | $100,000-500,000 | One-time event | Date interest arose: Apr 2021 Date interest ended: Mar 2024 |
Deciphering the immunopeptidomic landscape of COVID- 19 disease; NPI E Caron; co-investigator |
Canadian Institutes of Health Research (CIHR) | Institution | $100,000-500,000 | One-time event | Date interest arose: Apr 2021 Date interest ended: Mar 2024 |
Measuring the immune response to SARS-CoV-2 variants of concern – Pilar 1 CoVarrNet; Co-investigator |
Public Health Agency of Canada (PHAC) | Institution | $100,000-500,000 | One-time event | Date interest arose: Apr 2022 Date interest ended: Mar 2023 |
Persistence and potency of naturally-occuring or vaccine-induced memory T cells to SARS-CoV-2 variants; NPI H Decaluwe | Canadian Institutes of Health Research (CIHR) and Coalition for Epidemic Preparedness Innovation (CEPI) | Institution | $100,000-500,000 | One-time event | Date interest arose: Dec 2021 Date interest ended: Nov 2023 |
IRYIS study: Immune responses in young immunosuppressed children to COVID-19 vaccine NPI H Declauwe | Public Health Agency of Canada (PHAC) through CITF | Institution | $500,000-1,000,000 | One-time event | Date interest arose: Apr 2022 Date interest ended: Mar 2023 |
CHOIR study: Children and older teens immune response to SARS-CoV-2 in Montreal; NPI Kate Zinszer, co-PI | Canadian Institutes of Health Research (CIHR) | Institution | $100,000-500,000 | One-time event | Date interest arose: Apr 2021 Date interest ended: Mar 2022 |
Pediatric Network Expansion Study for the Montréal Site; Expansion of existing CITF-supported pediatric studies: Understanding Immune Responses to SARS-CoV-2 Infection and Vaccination in children aged 5-11 years (ENCORE); NPI Kate Zinszer, co- PI | Public Health Agency of Canada (PHAC) through CITF | Institution | $100,000-500,000 | One-time event | Date interest arose: Apr 2022 Date interest ended: Dec 2023 |
COVID-19 Vaccine Immunogenicity and Safety in Immunodeficient Patients (VISID); NPI J. Cowan, co-PI | Public Health Agency of Canada (PHAC) through CITF | Institution | $50,000-100,000 | One-time event | Date interest arose: June 2021 Date interest ended: Dec 2022 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Omicron breakthrough infection elicits superior antibody responses to SARS-CoV-2 variants than booster doses. Immunology2023 American Academy of Immunology (AAI) Annual Meeting, Washington DC, USA (SN, poster) | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: May 2023 |
Omicron breakthrough infection elicits superior antibody responses to SARS-CoV-2 variants than booster doses. Coronavirus Variants Rapid Response Network (CoVarrNet) Spring Meeting, Ottawa, Canada (SN, oral) | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: May 2023 |
Omicron breakthrough infection induces superior mucosal and humoral immunity to SARS-CoV-2 variants than booster vaccination. COVID-19 Immunity Task Force Scientific Meeting, Vancouver, Canada (JG, oral) | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: Apr 2023 |
Omicron breakthrough infection elicits superior antibody responses to SARS-CoV-2 variants than booster doses. 9th Montréal Immunology Meeting annual symposium, Montréal, Canada (SN, oral) | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: Oct 2022 |
Immunogenicity of Pfizer-BioNTech COVID-19 mRNA Vaccine in Recovered Individuals Depends on Symptomatology during Initial Infection. Keystone Symposia - "Viral Immunity: Basic Mechanisms and Therapeutic Applications (RJ3 - Rescheduled from January 2022)". Joint Meeting with "Respiratory Viruses: New Frontiers (J4 - Rescheduled from January 2022)", Keystone, Colorado, United States (SN, poster) | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: June 2022 |
Symptomatology During SARS-CoV-2 Infection Influences Vaccine Immunogenicity and Response to Variants of Concern. 34th Annual Canadian Society for Immunology Conference (CSI), Halifax, Canada (SN, poster) | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: June 2022 |
Immunogenicity of Pfizer- BioNTech COVID- 19 mRNA Vaccine in Recovered Individuals Depends | CIHR CITF/PHAC | N/A | N/A | One-time event | Date interest arose: Jan 2022 |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role | Organization | Funds allocated to | Total dollar amount | Recurrence | When the association happened |
---|---|---|---|---|---|
Founding member of the Clinical Immunology Network of Canada, a network of Canadian clinicians that are involved in the care of patients with primary immune deficiencies. Chair of the first Annual CINC Symposium to be held in Halifax in June 2022. Multiple pharmaceutical companies financially support the Network. |
Clinical Immunology Network - Canada (CINC) | Institution | $10,000- 50,000 | >1 time | Date interest arose: Since 2021 |
Active member of the Primary Immunodeficiency Treatment Consortium: A North-American consortium reuniting 42 distinct institutions working together to improve the care of children with immunodeficiencies |
Primary Immunodeficiency Treatment Consortium | N/A | N/A | >1 time | Date interest arose: Since 2014 |
Active member of the Clinical Immunology Society and member of the Women in Clinical Immunology Sciences committee of the Clinical Immunology Society |
Clinical Immunology Society | N/A | N/A | >1 time | Date interest arose: Since 2010 |
Active member of the European Society for Immunodeficiencies and former junior representative for Canada |
European Society for Immunodeficiencies | N/A | N/A | >1 time | Date interest arose: Since before 2010 |
Active member of the Federation of Clinical Immunology Societies, CSI representative |
Federation of Clinical Immunology Societies | N/A | N/A | >1 time | Date interest arose: Since 2021 |
Member of the Canadian Society for Immunology | Canadian Society for Immuology | N/A | N/A | >1 time | Date interest arose: Since 2010 |
Member of the Histiocyte Society | Histiocyte Society | N/A | N/A | >1 time | Date interest arose: Since 2020 |
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?Dr. Eve Dubé
Québec, Quebec
Dr. Eve Dubé is a medical anthropologist. She is affiliated with Quebec National Institute of Public Health and the Research Center of the CHU-Québec. She is also an invited professor in anthropology at Laval University. Her research focuses on social, cultural and ethical issues around infectious diseases prevention. Most of her research aims at understanding why people accept, refuse or hesitate to receive vaccines and why healthcare providers adhere or not to vaccination recommendation for themselves, their families and their patients. She is the lead investigator of the Social Sciences and Humanities Network of the Canadian Immunization Research Network. From 2013 to 2014, she was a member of the World Health Organization (WHO) working group on vaccine hesitancy and she is currently part of the WHO Global Advisory Committee on Vaccine Safety where she is mainly involved in vaccine risk communication.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Kyla Hildebrand
University of British Columbia
Vancouver, British Columbia
Dr. Kyla Hildebrand is a Pediatric Clinical Immunology and Allergy specialist and Clinical Associate Professor in the Department of Pediatrics at the University of British Columbia (UBC). Her subspecialty training was completed at the Hospital for Sick Children and University of Toronto. She completed a Master of Community Health Sciences program from the Dalla Lana School of Public Health, University of Toronto. She is a Clinical Investigator at the BC Children's Hospital Research Institute and Director of the Pediatric Clinical Immunology and Allergy Residency Training Program at UBC.
Dr. Hildebrand's clinical work involves assessing and managing complex patients presenting with allergic and immunological disorders including children requiring hematopoietic stem cell transplantation. She has been engaged with the Special Immunization Clinic (SIC) Network at UBC since 2014. She is a collaborator at the UBC site in the Canadian Health Infant Longitudinal Development (CHILD) study, designed to advance knowledge about the genetic and environmental determinates of atopic disease to determine how early life exposures relate to health and disease outcomes.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Co-Principal investigator, Special Immunization Clinic Network. COVID-19 Immunity Task Force: Optimizing COVID-19 immunization in patients with adverse events following immunization in the Special Immunization Clinic Network (S106) |
Canadian Immunization Research Network/Coalition for Epidemic Preparedness Innovations (CEPI) | Institution | $100,000- 500,000 | One-time event | Date interest arose: Jan 2021 Date interest ended: June 2024 |
Co investigator, COVID-19 Vaccine Immunogenicity and Safety in Immunodeficient Patients – VISID study | COVID19 Immunity Task Force |
Institution | >$1,000,000 | One-time event | Date interest arose: 2021 Date interest ended: 2023 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Volunteer; Medical expert, Children's and Women's Health Centre 1) Emergency Blood Management Committee and 2) PIDD Working group member. | Provincial Health Services Authority | >1 time | Date interest arose: 1) 2019 2) May 2020 Date interest ended: Ongoing |
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role | Organization | Funds allocated to | Total dollar amount | Recurrence | When the association happened |
---|---|---|---|---|---|
Member, Board of Directors of the CSACI | Canadian Society of Allergy and Clinical Immunology | Institution | N/A | >1 time | Date interest arose: 2017 Date interest ended: Ongoing |
Member, Medical Advisory Board | Immunity Canada (patient advocacy group) | Institution | N/A | >1 time | Date interest arose: 2021 Date interest ended: Ongoing |
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Kristin Klein
Alberta Health Services
Edmonton, Alberta
Dr. Kristin Klein is public health and preventive medicine specialist based out of Edmonton, Alberta. She holds two positions with Alberta Health Services, serving as Associate Provincial Medical Officer of Health for Communicable Disease Control and as a local Medical Officer of Health for Northern Alberta. Her educational background includes a Bachelor of Science from the University of Calgary, a medical degree and fellowship training in Public Health and Preventive Medicine from the University of Alberta. Prior to her role with AHS, Dr. Klein served as the Deputy Medical Officer of Health for the Government of Alberta. She has contributed to several provincial and national committees including representing the Council of Chief Medical Officers of Health as liaison member to NACI. She also holds a clinical appointment with the Faculty of Medicine and Dentistry at the University of Alberta.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Ms. Miranda O'Driscoll
Department of Health and Community Services
St. John's, Newfoundland and Labrador
Miranda O'Driscoll is the Provincial Disease Control Registered Nurse Specialist with the Department of Health and Community Services, Government of Newfoundland and Labrador. In her 16-year nursing career, Miranda has worked in a variety of roles as a registered nurse, all with a public health focus. Miranda's experience includes program policy planning, development, coordinating and implementation of communicable disease control programs, immunization standards and practice as well as public health programming for families at both a regional and provincial level. Miranda is a member of several federal committees whose work focus on similar strategies. Miranda has also played a vital role in the provincial response to COVID-19. Miranda received certification in Community Health through the Canadian Nurses Association and is currently working on her Masters in Public Health through Memorial University.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Jesse Papenburg
McGill University Health Centre
Montreal, Quebec
Dr. Jesse Papenburg is an Assistant Professor of Pediatrics and an Associate Member of the Department of Epidemiology, Biostatistics and Occupational Health at McGill University. He practices Pediatric Infectious Diseases and Medical Microbiology at the Montreal Children's Hospital of the McGill University Health Centre.
Dr. Papenburg obtained his medical degree from McGill University and completed residency and subspecialty training at the Montreal Children's Hospital. He then completed a research fellowship on the molecular virology of RNA respiratory viruses at Laval University and a MSc in epidemiology at McGill. As a clinician scientist, Dr. Papenburg's research is on the epidemiology of viral respiratory infections, with a focus on diagnostics to improve treatment and outcomes. He actively contributes to national and provincial guidelines on RSV immunoprophylaxis and influenza antiviral treatment.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Site PI, Investigator initiated study "INFORM: International, multi-centre, observational study to determine the molecular heterogeneity of RSV in children." |
MedImmune | Institution | $10,000-50,000 | One-time event | Date interest arose: Jan 2018 Date interest ended: July 2022 |
Site PI, Industry-led study. Merck 1654-004: A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants |
Merck | Institution | $100,000-500,000 | One-time event | Date interest arose: Sept 2021 Date interest ended: Dec 2023 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Anne Pham-Huy
Children's Hospital of Eastern Ontario (CHEO)
Ottawa, Ontario
Dr. Anne Pham-Huy completed her medical degree at the University of Ottawa in 2003 and her subspecialty training in pediatric infectious diseases at McGill University in 2008. She also pursued additional training in clinical immunology. Dr. Pham-Huy has been at the Children's Hospital of Eastern Ontario (CHEO) since 2009. She is the lead physician for the primary immunodeficiency clinic at CHEO. Her research interests include the diagnosis and management of primary immunodeficiencies, infections in the immunocompromised host and immunization in special populations. She is the program director for the pediatric infectious diseases training program. She is also the current chair for Immunize Canada, a not-for-profit coalition of organizations with a specific interest in promoting the understanding and use of vaccines.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Persistence of T cell Immunity in Children with SARS-CoV-2 and Household contacts (PITCH Study) | CHAMO Innovation Fund PSI Foundation |
Institution | CHAMO: $80,558 PSI: $248,000 |
One-time event | CHAMO: Date interest arose: March 25, 2021 PSI: Date interest arose: December 7, 2021 |
COVID-19 Vaccine Immunogenicity and Safety in Immunodeficient Patients – (VISID Study) | COVID-19 Immunity Task Force (CIFT) | Institution | $28,600 | One-time event | Date interest arose: September 1, 2021 Date interest ended: December 31, 2023 |
Natural Evolution of Serum Antibodies in Children and Adults with SARS-CoV-2 and Household Contacts: Persistence of Antibody Titers to COVID-19 in Households (PATCH Study) | Ontario COVID-19 Rapid Research Fund Funding, Provincial Innovation Fund CHAMO COVID-19 Innovation Fund | Institution | $926,492 $245,000 $89,973 |
One-time event | Date interest arose: Completed |
Special Immunization Clinic Network to investigate vaccine safety issues: Optimizing the clinical management of patients with contraindication to vaccination and those with adverse events following immunization (AEFI) as a platform for observational research |
CIHR | Institution | $133,000 | >1 time | Date interest arose: September 27, 2013 Date interest ended: Ongoing |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Vaccine Update COVID-19 Update Presented on Feb 8th 2025 at the Pediatric ID conference, Banff | N/A | Directly to the researcher | $750 | One-time event | Date interest arose: February 2025 |
6. Sponsored travel
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Describe the travel | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Feb 8, 2025 at the Pediatric ID conference, Banff | N/A | Directly to the researcher | $509 | One-time event | Date interest arose: February 2025 |
May 21, 2025 Iqaluit to give a talk on newborn screening for severe combined immunodeficiency where I also discussed the use of IVIG and SCIG | CSL Behring | N/A | <$3,000 | One-time event | Date interest arose: May 2025 |
7. Hospitality
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
Describe the hospitality | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Feb 8th 2025 at the Pediatric ID conference, Banff | N/A | Directly to the researcher | N/A | One-time event | Date interest arose: February 2025 |
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories above
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Describe the interest | Funds allocated to | Total dollar amount | Recurrence | When the interest happened |
---|---|---|---|---|
Chair of Immunize Canada | N/A | N/A | N/A | Date interest arose: November 2019 Date interest ended: Ongoing |
Dr. Ellen Rafferty
University of Alberta
Edmonton, Alberta
Dr. Ellen Rafferty is a Senior Principal Health Economist at the Institute of Health Economics (IHE) and an Assistant Professor in the Department of Medicine, University of Alberta. At IHE, Dr. Rafferty co-leads a portfolio of work on the epidemiologic and economic impact of infectious diseases and public health policies, in particular vaccination, using mathematical and statistical modelling methods. She has a PhD in epidemiology and health economics, and a Master of Public Health from the University of Saskatchewan. She is co-lead of CIRN's Modeling and Economics Research Network. Dr. Rafferty is interested in the incorporation of economics into immunization decision-making, and to that aim has presented to and worked with a variety of provincial and national organizations, including NACI, and the Alberta Advisory Committee on Immunization. She was a member of NACI's Economics Task Group that was charged with advising on the development of the process for incorporating economic evidence into vaccine recommendations and the guidelines for the economic evaluation of vaccination programs.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
As part of my health system impact fellowship, I was the primary author on a commentary on the inclusion of economics into vaccine policy decision-making. The dates are when I started my CIHR HSIF and when I published the article. (https://doi.org/10.1007/s41669-022-00347-1) | CIHR Health System Impact Fellowship (Postdoctoral salary support) | Institution | $100,000-500,000 | >One-time | Date interest arose: 2018 Date interest ended: 2022 |
I am a co-investigator on a grant about vaccination during the COVID- 19 pandemic. A few studies have come out of this, where I am a co- author. (http://dx.doi.org/10.1136/bmjopen-2021-055968; DOI: https://doi.org/10.1080/21645515.2021.2007707) |
CIHR Operating Grant: COVID-19 May 2020 Rapid Research Funding Opportunity (held by Shannon MacDonald) |
Institution | $100,000-500,000 | One-time event | Date interest arose: 2020 Date interest ended: 2022 |
I am a co-investigator on a grant assessing the impact of COVID-19 on routine school-based immunizations. | CIHR Operating Grant: Understanding the mitigating impact of the COVID-19 pandemic on children, youth and families in Canada. (held by Cordell Neudorf) |
Institution | $100,000-500,000 | One-time event | Date interest arose: 2021 Date interest ended: 2023 |
I was a co-author on a grant to build a transmission and economic model related to respiratory syncytial virus (RSV). I am a primary author on a publication of this work related to the costs associated with RSV disease (doi: 10.1007/s40273-022-01142-w.) |
Canadian Immunization Research Network (held by Shannon MacDonald) | Institution | $100,000-500,000 | One-time event | Date interest arose: 2019 Date interest ended: 2022 |
Was a co-author on a publication related to the cost-effectiveness of RSV immunization products. doi: 10.1016/j.vaccine.2024.126164. |
NA | NA | NA | One-time event | Date interest arose: 2023 Date interest ended: 2024 |
Was a co-author on a publication Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: A cost-benefit analysis. https://doi.org/10.14745/ccdr.v49i06a03 | NA | NA | NA | One-time event | Date interest arose: 2022 Date interest ended: 2023 |
Co-investigator on a grant titled 'Vaccination in a pandemic: Perspectives of equity seeking groups and healthcare providers on COVID-19 vaccination". |
Canadian Immunization Research Network (held by Shannon MacDonald) |
Institution | $100,000-500,000 | One-time event | Date interest arose: 2020 Date interest ended: 2022 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Membership on NACI's economic task group. | NACI | >One-time | Date interest arose: 2019 Date interest ended: 2023 |
Membership on NACI's RSV working group | NACI | >One-time | Date interest arose: 2023 Date interest ended: ongoing |
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
I have presented at a number of scientific meetings for projects related to vaccines. The titles of these presentations and the location of the scientific meeting I have presented at in the last 5 years include:
on pediatric shingles epidemiology in Alberta, CIC, 2020
When I received funding for these presentations it was through the grants described above or the institutions I was working at (University of Alberta/University of Saskatchewan) and they were solely to pay for my travel. I never received income for these presentations or funding from a company producing the intervention or health |
Alberta Health; Canadian Immunization Research Network, CIHR, Canadian Immunization Conference | Went directly to travel fees. | N/A | >1 time | Date interest arose: 2017 Date interest ended: Ongoing |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Tasha Ramsey
Nova Scotia Health
Halifax, Nova Scotia
Dr. Tasha Ramsey is a pharmacist who obtained her Bachelor of Science in Pharmacy degree in 2008 from Dalhousie University, her Pharmacy Residency diploma in 2009 from Kingston General Hospital and the University of Toronto, and her Post-Graduate Doctor of Pharmacy degree in 2013 from the University of British Columbia.
Dr. Ramsey is the Nova Scotia Health Clinical Therapeutics and Prophylactics Lead for Emerging and Re-Emerging Infections, including the Nova Scotia Health Vaccine Consult Service, and an Assistant Professor at Dalhousie University's Faculty of Health and Faculty Medicine. She is the co-chair of the Nova Scotia Emerging and Re-emerging Infections Therapeutics and Prophylactics Recommendation Group and the Canadian Society of Healthcare-Systems Pharmacy representative for Immunize Canada. Her research explores the role of pharmacists in infectious diseases prevention, testing, and treatment.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Co-investigator on the study: Addressing the problem of recommended but unfunded vaccines through a transitional stepped co-payment mechanism in pharmacies | Canadian Immunization Research Network Extension Grant | Institution | $150,000 | One-time event | Date interest arose: June 2023 Date interest ended: March 2024 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Presentation: "The Vax Facts: Protecting Against Measles, Mumps, Meningitis, and Pertussis One Shot At A Time!" for pharmacy professionals at the Dalhousie University Continuing Pharmacy Education 2025 Spring Refresher | Dalhousie University Continuing Pharmacy Education | Directly to the researcher | <$1,000 | One-time event | Date interest arose: March 29, 2025 Date interest ended: March 29, 2025 |
Presentation: "The Fantastic Four! A Review of Pneumococcal, RSV, COVID, And Influenza Vaccines" for pharmacy professionals at the Canadian Society of Healthcare- Systems Pharmacy Infectious Diseases Summit Webinar |
Canadian Society of Healthcare- Systems Pharmacy | Directly to the researcher | <$1,000 | One-time event | Date interest arose: November 30, 2024 Date interest ended: November 30, 2024 |
Presentation: “What’s New? A Review For Those Living With HIV Of Vaccines For Pneumococcus, RSV, COVID, And The Flu!” for pharmacy professionals at the Canadian HIV/AIDS Pharmacists Network’s CHAP Chat |
Canadian HIV/AIDS Pharmacists Network | Directly to the researcher | $1,000-5,000 | One-time event | Date interest arose: October 25, 2024 Date interest ended: October 25, 2024 |
Presentation: “Hit Me With Your Best (Respiratory Pathogen) Shot(s): Updates On The New Pneumococcal, RSV, COVID, And Influenza Vaccine Recommendations.” for pharmacy professionals at the Pharmacy Association of Nova Scotia’s 2024 Nova Scotia Pharmacy Conference. |
Pharmacy Association of Nova Scotia | Directly to the researcher | <$1,000 | One-time event | Date interest arose: October 19, 2024 Date interest ended: October 19, 2024 |
Presentation: “Publicly Funded Vaccine Assessments: Let’s Give It A Shot!.” for pharmacy professionals at the Pharmacy Association of Nova Scotia’s 2023 Nova Scotia Pharmacy Conference |
Pharmacy Association of Nova Scotia | Directly to the researcher | <$1,000 | One-time event | Date interest arose: October 15, 2023 Date interest ended: October 15, 2023 |
Presentation: “COVID-19 Pharmacotherapy and Vaccination 101.” for pharmacy professionals at the Prince Edward Island Pharmacists Association Continuing Education Conference |
Dalhousie University Continuing Pharmacy Education | Directly to the researcher | <$1,000 | One-time event | Date interest arose: May 7, 2022 Date interest ended: May 7, 2022 |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories above
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Describe the interest | Funds allocated to | Total dollar amount | Recurrence | When the interest happened | Describe the interest |
---|---|---|---|---|---|
Canadian Society of Healthcare-Systems Pharmacy representative for Immunize Canada | N/A | N/A | N/A | Date when interest arose: July 2019 | Canadian Society of Healthcare-Systems Pharmacy representative for Immunize Canada |
Dr. Karina Top
University of Alberta
Edmonton, Alberta
Dr. Karina Top is a pediatric infectious disease physician and clinician-scientist in vaccine research. She is a Professor in the Department of Pediatrics and Adjunct Professor in the School of Public Health at the University of Alberta. Dr. Top completed medical school and pediatric residency at Dalhousie University in Halifax, NS, followed by fellowship training in pediatric infectious diseases and a Master of Science (Epidemiology) at Columbia University in New York. From 2011 to 2023, she was on the faculty of Dalhousie University and IWK Health where she established a research program in vaccine safety and vaccination of special populations.
Dr. Top is the Principal Investigator of the International Network of Special Immunization Services and co-Principal Investigator of the Canadian Immunization Research Network's Special Immunization Clinic Network. She was awarded the CIHR-CEPI Leadership Award for Excellence in Vaccine Research in 2021. Dr. Top has over 100 peer-reviewed publications and is a member of the Brighton Collaboration Science Board and Executive member of the Canadian Association for Immunization Research Evaluation and Education. She has previously contributed to vaccine safety surveillance and research as an investigator with the Canadian Immunization Monitoring Program Active, external expert to the NACI Vaccine Safety Working group, and as a consultant with the World Health Organization European Regional Office.
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Co-Investigator, Clinical Sample Expertise Core, Striving for Pandemic Preparedness- Alberta Research Consortium | Government of Alberta | Institution | $100,000-$150,000 | 1 time | Date interest arose: Oct 2024 Date interest ended: ongoing |
Principal Investigator, International network of special immunization services | Coalition for Epidemic Preparedness Innovations |
Institution | >$1,000,000 | 1 time | Date interest arose: Nov 2022 Date interest ended: ongoing |
Principal Investigator, Leadership Award in Vaccine Research | CIHR/CEPI | Institution | $500,000-1,000,000 | 1 time | Date interest arose: Nov 2021 Date interest ended: ongoing |
Co-Principal Investigator, Canadian Immunization Research Network |
CIHR/PHAC | Institution | >$1,000,000 | >1 time | Date interest arose: March 2014 Date interest ended: ongoing |
Investigator, Canadian Immunization Monitoring Program ACTive (IMPACT) project |
PHAC | Institution | >$1,000,000 | >1 time | Date interest arose: July 2012 Date interest ended: ongoing |
Co-PI, Pediatric Outcomes imProvement through Coordination of Research Networks (POPCORN) |
CIHR | Institution | >$1,000,000 | >1 time | Date interest arose: March 2022 Date interest ended: ongoing |
Co-PI, various studies of COVID-19 vaccination in immunocompromised populations |
PHAC via COVID- 19 Immunity Task Force |
Institution | >$1,000,000 | >1 time | Date interest arose: March 2021 Date interest ended: Sept 2023 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual property Footnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer and Source of funding (if applicable) |
Total dollar amount | Recurrence | Key dates | Describe the paid or voluntary work, including your role |
---|---|---|---|---|---|
Paid consultant with World Health Organization to conduct vaccine safety training in European region, funds paid to my academic account |
WHO | $10,000-50,000 (total) | >1 time | Date interest arose: August 2018 Date interest ended: Jan 2023 |
Paid consultant with World Health Organization to conduct vaccine safety training in European region, funds paid to my academic account |
Expert testimony related to vaccine safety, funds paid to my academic account |
Ontario Ministry of the Attorney General | $5,000-10,000 | One-time event | Date interest arose: Feb 2020 Date interest ended: Dec 2020 |
Expert testimony related to vaccine safety, funds paid to my academic account |
Global Pertussis Initiative, volunteer expert/presenter | Sanofi sponsored | 0 (declined honorarium) | One-time event | Date interest arose: Nov 2021 Date interest ended: Dec 2021 |
Global Pertussis Initiative, volunteer expert/presenter |
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Re-emerging infections in children, Presented at 33rd Pediatric Infectious Diseases Conference | Pediatric Infectious Diseases Conference | Directly to the researcher | $1,000-5,000 (reimbursement of travel only, declined honorarium) | One-time event | Date interest arose: Feb 2025 Date interest ended: Feb 2025 |
Multiple presentations on vaccine safety surveillance, adverse events, and COVID-19 vaccines at Canadian Immunization Conference 2024 | CIHR/Canadian Association of Immunization Research Evaluation and Education | Directly to the researcher | $1,000-5,000 (reimbursement of travel only, declined honorarium) | One-time event | Date interest arose: Nov 2024 Date interest ended: Nov 2024 |
Understanding biological mechanisms of AESIs and enhancing capacity of vaccine safety studies in LMICs at World Vaccine Congress | Terrapin | Directly to the researcher | $1,000-5,000 (reimbursement of travel only) | One-time event | Date interest arose: Apr 2024 Date interest ended: Apr 2024 |
International Network of Special Immunization Services: A global network to advance vaccine safety at International Precision Vaccines Conference | International Precision Vaccines Conference | Directly to the researcher | $1,000-5,000 (reimbursement of travel only) | One-time event | Date interest arose: Oct 2023 Date interest ended: Oct 2023 |
Advancing the science of vaccine safety: Introducing the International Network of Special Immunization Services at International Society of Pharmacovigilence Annual Meeting | International Society of Pharmacovigilence | Directly to the researcher | $1,000-5,000 (reimbursement of travel only) | One-time event | Date interest arose: Sept 2022 Date interest ended: Sept 2022 |
Various unpaid presentations on vaccine safety, vaccines in special populations, COVID-19 vaccines to scientific, academic, public health and patient groups in Canada, US, Australia, Europe |
N/A | N/A | 0 | Date interest arose: Aug 2020 Date interest ended: ongoing |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role |
Organization | Funds allocated to |
Total dollar amount |
Recurrence | When the association happened |
---|---|---|---|---|---|
Executive Board Member (volunteer) | Canadian Association of Immunization Research Evaluation and Education | N/A | 0 | >1 time | Date interest arose: June 2019 Date interest ended: ongoing |
Science Board member (volunteer) | Brighton Collaboration | N/A | 0 | >1 time | Date interest arose: Jan 2022 Date interest ended: ongoing |
9. Public statements about the guideline topic
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
Describe the statement, including where it was published | Funds allocated to | Total dollar amount | Recurrence | When the statement happened |
---|---|---|---|---|
Opinion editorial in Edmonton Journal with co-author J Robinson: "Smith must encourage measles vaccinations to fight outbreak" | N/A | 0 | One-time | Date interest arose: Jun 2025 Date interest ended: Jun 2025 |
Opinion editorial in Calgary Herald and Edmonton Journal 2024 Jun 17 with co-authors S Wong, Constantinescu C, Jadavji T, Kellner J, Vanderkooi O, Robinson J: Pediatric and infectious disease specialists urge parents to be aware of vaccine misinformation | N/A | 0 | One-time | Date interest arose: Jun 2024 Date interest ended: Jun 2024 |
Publication of empiric data supporting use of rotavirus vaccination in biologic-exposed infants: Fitzpatrick T, Alsager K, Sadarangani M, Pham-Huy A, Murguía-Favela L, Morris SK, Seow CH, Piché-Renaud PP, Jadavji T, Vanderkooi OG, Top KA, Constantinescu C; Special Immunization Clinic Network investigators. Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health. 2023 Sep;7(9):648-656. doi: 10.1016/S2352-4642(23)00136-0. Epub 2023 Jun 27. PMID: 37390832. |
N/A | 0 | One-time | Date interest arose: Jun 2023 Date interest ended: Sept 2023 |
Regular media interviews (broadcast and print) with local, national, international media outlets related to COVID-19 vaccination and measles | N/A | N/A | >1 time | Date interest arose: June 2020 Date interest ended: ongoing |
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Dr. Sarah Wilson
Public Health Ontario
Toronto, Ontario
Dr. Sarah Wilson is a public health physician/medical epidemiologist at Public Health Ontario PHO where she works closely with the Immunization and Vaccine-Preventable Diseases team within the Communicable Diseases and Emergency Preparedness Response Department. In this role, she provides support to the surveillance of vaccine-preventable diseases, immunization coverage, vaccine safety, outbreak management, and participates in applied research. Sarah's research interests include applied vaccine program evaluation and immunization coverage assessment using a range of data sources including both routine surveillance and administrative data. She is a Fellow of the Royal College of Physicians and Surgeons in Public Health and Preventive Medicine and a graduate of the Canadian Field Epidemiology Program. She is an Assistant Professor at the Dalla Lana School of Public Health at the University of Toronto and an Adjunct Scientist at ICES (formerly known as the Institute for Clinical Evaluative Sciences).
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Funded grant Role: Co-investigator. Title: Does a reduced dose RotaTeq (RV5) vaccine schedule translate into a higher incidence of rotavirus infections compared to approved RV5 schedules |
CIRN | Institution | $100,000 – 500,000 | One-time event | Date interest arose: 2023 Date interest ended: Ongoing |
Funded grant Role: Co-investigator Title: Impact of vaccination programs on human papillomavirus outcomes in Ontario |
CIRN | Institution | $100,000 – 500,000 | One-time event | Date interest arose: 2022 Date interest ended: Ongoing |
Funded grant Role: Co-investigator Title: Impact of the COVID-19 pandemic on routine childhood and other primary care immunizations in Ontario, Canada |
CIRN | Institution | $100,000 – 500,000 | One-time event | Date interest arose: 2022 Date interest ended: Ongoing |
Funded grant Role: Co-investigator Title: COVID-19 vaccination in pregnancy: A province-wide epidemiological assessment of safety and effectiveness using the BORN Ontario Registry. |
COVID-19 Immunity Task Force (CITF) | Institution | $100,000 – 500,000 | One-time event | Date interest arose: 2021 Date interest ended: 2022 |
Funded grant Role: Collaborator Title: Canadian Immunization Research Network: COVID-19 vaccine readiness |
CIHR | Institution | >$1,000,000 | One-time event | Date interest arose: 2021 Date interest ended: 2022 |
Funded grant Role: co-investigator Title:Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) COVID-19 vaccine post-market studies |
COVID-19 Immunity Task Force (CITF) | Institution | >$1,000,000 | One-time event | Date interest arose: 2021 Date interest ended: 2023 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Public health physician | Public Health Ontario | N/A | Date interest arose: June 2012 Date interest ended: Ongoing |
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role | Organization | Funds allocated to | Total dollar amount | Recurrence | When the association happened |
---|---|---|---|---|---|
Representative of Public Health Ontario | Immunization Canada | N/A | N/A | >1 time | Date interest arose: 2019 Date interest ended: Ongoing |
Academic affiliation and member | Centre for Vaccine-Preventable Diseases, University of Toronto | N/A | N/A | >1 time | Date interest arose: 2017 Date interest ended: Ongoing |
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Executive secretary
Dr. Matthew Tunis
Liaison representatives
Association of Medical Microbiology and Infectious Disease Canada
Dr. Jeannette Comeau, Halifax, NS
Disclosure of affiliations and interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
A study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants, Co-Investigator | GlaxoSmithKline Biologicals | Institution | $100,000-500,000 | >1 time | Date interest arose: Oct 2019 Date interest ended: Dec 2024 |
A Phase 3, multicenter, randomized, double-blind, active comparator controlled study to elevate the safety and tolerability of V114 in healthy infants (PNEU - LINK), Co-Investigator | Merck Canada Inc. | Institution | $100,000-500,000 | >1 time | Date interest arose: Apr 2019 Date interest ended: Mar 2022 |
A Phase II, randomized, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers (GS1901), Co-Investigator | GlaxoSmithKline Biologicals | Institution | $100,000-500,000 | >1 time | Date interest arose: Oct 2019 Date interest ended: Dec 2024 |
A Phase 3, multicenter, randomized, double-blind, active comparator controlled study to elevate the safety and tolerability of V114 in healthy infants (PNEU - LINK), Co-Investigator | Merck Canada Inc. | Institution | $100,000-500,000 | >1 time | Date interest arose: Apr 2019 Date interest ended: Mar 2022 |
A Phase II, randomized, observer-blind, placebo controlled multi-country study to assess the safety, reactogenicity and immunogenicity of a single intramuscular dose of GSK Biologicals' investigational RSV Maternal unadjuvanted vaccine (GSK3888550A), in healthy pregnant women aged 18 to 40 years and infants born to vaccinated mothers, Co-Investigator | GlaxoSmithKline Biologicals | Institution | $50,000-100,000 | >1 time | Date interest arose: Dec 2019 Date interest ended: Dec 2024 |
A phase 1/2 study to evaluate safety, reactogenicity and immunogenicity of GSK Biologicals' RSV investigational vaccine based on viral proteins encoded by chimpanzee-derived adenovector (ChAd155-RSV) (GSK3389245A) in infants,Co-Investigator | GlaxoSmithKline Biologics | Institution | $50,000-100,000 | >1 time | Date interest arose: Apr 2019 Date interest ended: Mar 2024 |
A phase III, double-blind, randomized, placebo-controlled study to evaluate the safety, reactogenicity and immune response of a single intramuscular dose of unadjuvanted RSV Maternal vaccine, in high-risk pregnant women aged 15 to 49 years and infants born to the vaccinated mothers. (GS2101),Co-Investigator | GlaxoSmithKline Inc | Institution | $50,000-100,000 | >1 time | Date interest arose: July 2019 Date interest ended: Aug 2023 |
A phase 3 trial to evaluate the efficacy and safety of a respiratory syncytial virus (RSV) prefusion F subunit vaccine in infants born to women vaccinated during pregnancy (PF2001),Co-Investigator | Pfizer | Institution | $50,000-100,000 | >1 time | Date interest arose: Jan 2021 Date interest ended: Jan 2026 |
A phase III double-blind study to assess safety and efficacy of an RSV maternal unadjuvanted vaccine, in pregnant women and infants born to vaccinated mothers (GRACE) (GS2002),Co-Investigator | Pfizer | Institution | $100,000-500,000 | >1 time | Date interest arose: Feb 2021 Date interest ended: Feb 2026 |
Phase I/II trial to evaluate safety, tolerability, immunogenicity of a prophylactic plasmid DNA vaccine for SARS-SoV-2 [Covigenix VAS-001] in healthy adults from 18 to <85 years of age (ET2001),Co-Investigator | Entos Pharmaceuticals Inc. | Institution | $500,000-1,000,000 | >1 time | Date interest arose: Mar 2021 Date interest ended: Mar 2026 |
A phase 1/2, randomized, observer-blind, dose-escalation, placebo-controlled study to evaluate the safety tolerability, and immunogenicity of the COVID-19 (SARS-CoV-2) vaccine candidate (VBI-2902a) in healthy adults (VB2001),Co-Investigator | VBI Vaccines Inc | Institution | $500,000-1,000,000 | >1 time | Date interest arose: Mar 2021 Date interest ended: Mar 2026 |
Safety and immunogenicity of a pneumococcal conjugate vaccine when administered concomitantly with routine pediatric vaccines in healthy toddlers and infants (SP2001),Co-Investigator | Sanofi Pasteur Inc. | Institution | $100,000-500,000 | >1 time | Date interest arose: October 2020 Date interest ended: April 2026 |
A phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above (GS2003),Co- Investigator | GlaxoSmithKline Inc. | Institution | $500,000-1,000,000 | >1 time | Date interest arose: July 2021 Date interest ended: July 2026 |
A phase 2/3, two-part, open-label, dose-escalation, age de-escalation and randomized, observer-blind, placebo-controlled expansion study to evaluate the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273 SARS-CoV-2 vaccine in healthy children 6 months to less than 12 years of age (MO2102),Co- Investigator | ModernaTX, Inc. | Institution | $100,000-500,000 | >1 time | Date interest arose: Nov 2021 Date interest ended Oct 2026 |
A phase 2b/3 double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of MK-1654 in healthy pre-term and full-term infants (MK2001),Co-Investigator | Merck & Co., Inc. | Institution | $500,000-1,000,000 | >1 time | Date interest arose: Dec 2021 Date interest ended: Dec 2026 |
A Phase 1 randomized, observer-blind, dose escalation study to evaluate the safety, reactogenicity and immunogenicity of an mRNA based monovalent influenza vaccine candidate in healthy younger and older adults (GS2203),Co-Investigator | GlaxoSmithKline Inc. | Institution | $100,000-500,000 | >1 time | Date interest arose: May 2022 Date interest ended: July 2027 |
A Phase 1/2a Open-Label Dose Ranging and Observer-Blind Placebo-Controlled. Safety and Immunogenicity Study of mRNA-1647 Cytomegalovirus Vaccine in Female and Male Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age. (MO2202),Co-Investigator | ModernaTX, Inc. | Institution | $100,000-500,000 | >1 time | Date interest arose: Mar 2023 Date interest ended: Mar 2028 |
A non-randomized, open label, multi-country cohort study to describe the safety the study participants who received RSVPreF3 maternal vaccination (any dose) from previous RSV MAT studies (RSV MAT-001, RSV MAT004, RSV MAT-010, RSV MAT-011, RSV MAT-009, RSV MAT-012 and RSV MAT-039) during any pregnancy conceived post vaccination/control. (GS2204),Co-Investigator | GlaxoSmithKline Inc. | Institution | $50,000-100,000 | >1 time | Date interest arose: Apr 2023 Date interest ended: Apr 2028 |
A randomized, observer-blind, dose-escalation phase I/II clinical trial of COVAC vaccine in healthy individuals (VI2001),CO-Investigator | Vaccine and Infectious Disease Organization- International Vaccine Centre (VIDO–InterVac) | Institution | >$1,000,000 | >1 time | Date interest arose: Jan 2021 Date interest ended: Jan 2026 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Please provide any additional comments, if applicable:
I have never received speaking fees for any presentations/lectures. I have received travel honorariums for conferences and lectures, but never any funds from a pharmaceutical company or related third party.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
Please provide any additional comments, if applicable:
I have received funds from WHO for travel to conferences and meetings, and travel honorariums from conferences directly, but never any funds from a pharmaceutical company or related third party.
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Association for Immunization Research and Evaluation
Dr. Sarah Buchan, Toronto, ON
Disclosure of affiliations and interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Funded grant Role:Principal investigator Title:Using linked laboratory and health administrative data to study respiratory syncytial virus (RSV)-associated hospitalizations and mortality in adults in Ontario. |
CIHR | Institution | $100,000-500,000 | One-time event | Date interest arose: October 2021 Date interest ended: ongoing |
Funded grant Role:Principal investigator Title:Burden, cost, and development of asthma related to severe RSV infections |
SickKids-Canadian Institutes of Health Research | Institution | $100,000-500,000 | One-time event | Date interest arose: February 2019 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Using dynamic transmission and economic modelling to inform RSV immunization policy |
Canadian Immunization Research Network | Institution | $100,000-500,000 | One-time event | Date interest arose: June 2019 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:COVID-19 Vaccination among People Living with HIV: Immunogenicity, Effectiveness, and Safety |
COVID-19 Immunity Task Force | Institution | >$1,000,000 | One-time event | Date interest arose: April 2021 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Teasing apart the differential impact of variants of concern on COVID-19 severity and health inequities: a population-based genomic epidemiological investigation in Ontario and British Columbia |
CIHR | Institution | $100,000-500,000 | One-time event | Date interest arose: April 2021 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Pregnant and lactating individuals & newborns COVID-19 vaccination study. |
CIHR | Institution | $500,000-1,000,000 | One-time event | Date interest arose: April 2021 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:COVID-19 vaccination in pregnancy: A province-wide epidemiological assessment of safety and effectiveness using the BORN Ontario Registry. |
Public Health Agency of Canada (PHAC): COVID-19 Immunity Task Force (CITF)/Vaccine Surveillance Reference Group (VSRG). | Institution | $500,000-1,000,000 | One-time event | Date interest arose: April 2021 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Burden of COVID-19 among people living with HIV in Ontario |
CIHR | Institution | $500,000-1,000,000 | One-time event | Date interest arose: March 2021 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:COVID-19 variant supplement - The COVID-19 Ontario Pregnancy Event (COPE) Network: Assessing the impact of COVID-19 in pregnancy on maternal, fetal and newborn health. |
CIHR | Institution | $50,000-100,000 | One-time event | Date interest arose: March 2021 Date interest ended: ongoing |
Funded grant Role:Collaborator Title:Canadian Immunization Research Network: COVID-19 vaccine readiness. |
CIHR | Institution | >$1,000,000 | One-time event | Date interest arose: January 2021 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) COVID-19 vaccine post-market studies |
COVID-19 Immunity Task Force (CITF)/Vaccine Surveillance Reference Group (VSRG). | Institution | >$1,000,000 | One-time event | Date interest arose: December 2020 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Effectiveness of influenza vaccination during pregnancy on laboratory-confirmed seasonal influenza among infants under 6 months of age |
Canadian Immunization Research Network | Institution | $100,000-500,000 | One-time event | Date interest arose: June 2019 Date interest ended: ongoing |
Funded grant Role:Co-investigator Title:Influenza vaccines, statins, and laboratory-confirmed influenza outcomes in older adults: can vaccines and statins reduce the burden of influenza? |
CIHR | Institution | $100,000-500,000 | One-time event | Date interest arose: October 2018 Date interest ended: ongoing |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Invited Presentation Myocarditis/pericarditis following mRNA vaccines: Passive vaccine safety surveillance data from Ontario, Canada ACIP COVID-19 Vaccines Work Group meeting |
N/A | N/A | N/A | One-time event | Date interest arose: January 2022 |
Invited Presentation Preliminary VE estimates for Omicron for Ontario, Canada WHO COVID-19 VE Methods Forum |
N/A | N/A | N/A | One-time event | Date interest arose: January 2022 |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organization which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role | Organization | Funds allocated to | Total dollar amount | Recurrence | When the association happened |
---|---|---|---|---|---|
Role:Faculty Member Centre for Vaccine Preventable Diseases, Dalla Lana School of Public Health, University of Toronto |
University of Toronto | N/A | N/A | N/A | Date interest arose: 2019 Date interest ended: ongoing |
Role:Member Institute for Pandemics, Dalla Lana School of Public Health, University of Toronto |
University of Toronto | N/A | N/A | N/A | Date interest arose: 2021 Date interest ended: ongoing |
Role:Member Canadian Association for Immunization Research and Evaluation |
CAIRE | N/A | N/A | N/A | Date interest arose: 2017 Date interest ended: ongoing |
Role:Member Canadian Immunization Research Network |
Dalhousie University | N/A | N/A | N/A | Date interest arose: 2015 Date interest ended: ongoing |
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Immunization Committee
Dr. Davinder Singh, Winnipeg, Manitoba
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Please provide any additional comments, if applicable:
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?Footnote*
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Indigenous Nurses Association
Ms. Lea Bill, Siksika, AB
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Public Health Association
Ms. Antonella Pucci, Ottawa, ON
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role | Organization | Funds allocated to | Total dollar amount | Recurrence | When the association happened |
---|---|---|---|---|---|
Employed as Manager, Immunization Initiatives at the Canadian Public Health Association responsible for managing Immunize Canada, a national coalition of nongovernmental, professional, health, government and private sector organizations dedicated to promoting the benefits of immunization. Immunize Canada has a special interest in promoting the understanding and use of vaccines approved for use in Canada according to the recommendations of the National Advisory Committee on Immunization (NACI). | Immunize Canada | Institution | $100,000-500,000 | >1 time | Date interest arose: May 2022 Date interest ended: Ongoing |
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Pharmacists Association
Ms. Emilie Zannis, Ottawa ON
Disclosure of affiliations and interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organization which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Paediatric Society
Dr. Dorothy Moore, Montréal, QC
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary work
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
Describe the paid or voluntary work, including your role | Employer | Recurrence | Key dates |
---|---|---|---|
Canadian Paediatric Society Infectious Diseases and Immunization Committee | Voluntary, not paid | N/A | Date interest arose: 1999 Date interest ended: Ongoing |
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associations
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
Describe the association, including your role | Organization | Funds allocated to | Total dollar amount | Recurrence | When the association happened |
---|---|---|---|---|---|
Canadian Paediatric Society (b) | member | N/A | N/A | N/A | Date interest arose: 1984 Date interest ended: Ongoing |
Association of Medical Microbiology and Infectious Diseases, Canada (b) | member | N/A | N/A | N/A | Date interest arose: 1985 Date interest ended: Ongoing |
Infectious Diseases Society of America (b) | member | N/A | N/A | N/A | Date interest arose: 1986 Date interest ended: Ongoing |
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Council of Chief Medical Officers of Health
Dr. Martin Lavoie, Vancouver, BC
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactc agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Center for Disease Control and Prevention
Ms. Jessica MacNeil, Atlanta, Georgia, USA
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Indigenous Physicians Association of Canada
Ms. Melanie Osmack, Vancouver, BC
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Society of Obstetrics and Gyneacologists
Dr. Eliana Castillo, Calgary, AB
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in research
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Describe the research activity, including your role | Source of funding | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Principal Investigator Enhancing Vaccine Conversations: An Innovative Skill-building Course and Learning Solution for Healthcare Providers Addressing Vaccination in pregnancy | Pfizer Canada | Institution | $50,000-100,000 | One-time event | Date interest arose: September 2023 Date interest ended: August 2024 |
Co-Investigator Parental acceptability of emerging respiratory syncytial virus (RSV) immunization strategies in Canada | CIRN Canadian Immunization Research Network | Institution | $100,000- 500,000 | One-time event | Date interest arose: May 2023 Date interest ended: April 2025 |
Principal Investigator Adapting, Implementing and Evaluating MumBubVax in Canada: An Intervention to Protect Every Mom and Every Baby | CIRN Canadian Immunization Research Network | Institution | $100,000- 500,000 | One-time event | Date interest arose: November 2022 Date interest ended: October 2024 |
Co-Investigator Supporting Canadian health service users with decision making on COVID-19 vaccination during pregnancy and lactation | PHAC – Immunization Partnership Fund | Institution | $100,000- 500,000 | One-time event | Date interest arose: July 2021 Date interest ended: June 2023 |
Principal Investigator Implementation of COVID-19 Vaccination in Alberta and Improving the Public Health Impact of Vaccinations for Mother-Infant Health | Calgary Health Foundation | Institution | $100,000- 500,000 | One-time event | Date interest arose: June 2021 Date interest ended: June 2025 |
Adapting, Implementing and Evaluating MumBubVax in Canada: An Intervention to Protect Every Mom and Every Baby | CIRN Canadian Immunization Research Network | Institution | $100,000- 500,000 | One-time event | Date interest arose: November 2020 Date interest ended: March 2024 |
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking fees
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
Describe the presentation | Source of funding (if applicable) | Funds allocated to | Total dollar amount | Recurrence | Key dates |
---|---|---|---|---|---|
Facilitated a meeting titled: RSV Maternal Immunization Consultation | Pfizer | Directly to the researcher | $1,000-5,000 | One-time event | Date interest arose: June 7, 2022 Date interest ended: June 15, 2022 |
Speaker at Canadian Association of Perinatal and Women's Health Nurses (CAPWHN) Seminars: Covid-19 Vaccination in Pregnancy | Moderna | N/A | N/A I did not receive any payment | One-time event | Date interest arose: October 12, 2022 |
Speaker at: Maternal Immunization Experts Meeting (online): The Importance of Trusted Communication During Pregnancy: COVID-19 Effects and Fake News | Pfizer | N/A | N/A I did not receive any payment | One-time event | Date interest arose: December 9, 2022 |
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organisation which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Canadian Nurses Association
Ms. Margaret McIntyre, Toronto, ON
Disclosure of Affiliations and Interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organization which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
College of Family Physicians of Canada
Dr. Jen Potter, Winnipeg, MB
Disclosure of affiliations and interests from the last 3 years
1. Participation in researchFootnote*
Have you, your spouse/partner, or your immediate family members participated (e.g., as a trial investigator) in research related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Research that will be (or is likely to be) a component of a guideline recommendation on a topic
- Research related to a competing intervention that will be (or is likely to be) relevant to the guideline recommendations
- Research related to a company that produces a specific intervention under consideration in the guideline, but not related to that specific intervention
Please provide any additional comments, if applicable:
As the CEO/Chair of 19 To Zero, I lead a great deal of vaccine uptake related work, particularly for COVID-19. These grants are largely focused on increasing COVID-19 vaccine uptake, although some of the PHAC grants will focus on other routine vaccinations as well.
2. Equity ownershipFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned stock, stock options, or other ownership interests in a company that manufactures or promotes a health technology related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
3. Intellectual propertyFootnote*
Does you, your spouse/partner, or your immediate family members own or have owned patents or copyrights, and/or received royalties from these rights related to a health technology relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
4. Paid and voluntary workFootnote*
Have you, your spouse/partner, or your immediate family members participated in paid of voluntary work relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Employment in any capacity by the manufacturer of a health technology assessment under consideration
- Membership on a board of directors for a manufacturer of a health technology under consideration
5. Scientific meetings/lectures and speaking feesFootnote*
Have you, your spouse/partner, or your immediate family members delivered presentations or lectures in scientific meetings, which are relevant to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Presentation at a scientific meeting (open or closed) in relation to an intervention or health technology that could be part of clinical practice guideline recommendations
- Receiving income from lectures or other forms of teaching related to the health technology that could be part of a clinical practice guideline
- Funding from the company producing the intervention or health technology, a competitor, or from a third party on behalf of the company / competitor to speak at conference, scientific meeting or education facility for any purpose.
6. Sponsored travelFootnote*
Have you, your spouse/partner, or your immediate family members received funding or sponsorship for travel that was related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Any domestic or international travel either personally or to family or friends, funded in part or whole by a pharmaceutical company (or other company producing a health technology of interest) or related third party
7. HospitalityFootnote*
Have you, your spouse/partner, or your immediate family members received any hospitality or gifts from a third party as part of an activity related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Example
- Hospitality or gifts provided by a pharmaceutical company (or other company producing a health technology of interest) as part of a publicity or awareness-raising campaign
8. Sponsorship or associationsFootnote*
Have you, your spouse/partner, or your immediate family members been associated with an organization related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Involvement (as a general member or as part of organization's management) in an organization which receives direct funding or sponsorship from a pharmaceutical company (or other company producing a health technology of interest)
- Involvement (as a general member or as part of organization's management) in a non-profit or advocacy organization that may have a vested interest in the guideline topic
9. Public statements about the guideline topicFootnote*
Have you, your spouse/partner, or your immediate family members published any statements or opinions related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans?
Examples
- Advocating for a change in policy in relation to an intervention that may be part of the guideline scope
- Individual has made public statement advocating that a intervention or health technology under consideration should or should not be recommended
10. Other relevant disclosures related to the guideline topic that do not fit the categories aboveFootnote*
Have you, your spouse/partner, or your immediate family members have any other interests related to vaccines used for the prevention of infection and disease and the use of certain prophylactic agents (e.g. immunoglobulins) for humans that do not fit in the categories above?
Ex-officio representatives
Biologic and Radiopharmaceutical Drugs Directorate
Dr. Co Pham
Health Canada
Ottawa, ON
Directorate of Force Health Protection
Dr. Kirsten Barnes
National Defense and the Canadian Armed Forces
Ottawa, ON
Vaccine Preventable Diseases (VPD) Surveillance
Ms. Kristyn Franklin
Public Health Agency of Canada
Ottawa, ON
Centre for Immunization Surveillance and Programs (CISP)
Ms. Erin Henry
Public Health Agency of Canada
Ottawa, ON
Marketed Health Products Directorate
Mr. Patrick Fandja
Health Canada
Ottawa, ON
National Microbiology Laboratory
Dr. Michael Routledge
Public Health Agency of Canada
Winnipeg, MB
Vaccine Safety Surveillance
Ms. Tonja Stothart
Public Health Agency of Canada
Ottawa, ON
First Nations and Inuit Health Branch
Dr. Tom Wong
Indigenous Services Canada
Ottawa, ON
Public Health Ethics Consultative Group (PHECG)
Ms. Mireille Lacroix
Ottawa, ON
Routine Programs and Supply Chain
Ms. Jacqueline Kosche
Public Health Agency of Canada
Ottawa, ON
- Footnote *
-
None to declare
Page details
- Date modified: